CardioVascular and Interventional Radiology

, Volume 41, Issue 7, pp 1081–1088 | Cite as

Evaluating the Feasibility of Isolated Pancreatic Perfusion for Chemotherapy Using Computed Tomography: An Experimental Study in Pig Models

  • Satoru Murata
  • Shiro Onozawa
  • Daisuke Yasui
  • Tatsuo Ueda
  • Fumie Sugihara
  • Akira Shimizu
  • Kenichi Suzuki
  • Mitsuo Satake
Laboratory Investigation



Percutaneous isolated pancreatic perfusion (PIPP) is performed along with interventional radiology techniques to obtain high drug concentration by occluding the arterial inlet and venous outlet of the pancreas. The experimental study aimed to evaluate the contrast distribution in PIPP under different flow rates with or without anterior mesenteric artery (AMA) occlusion.

Materials and Methods

This study was approved by a local animal experiment ethics committee. Nine pigs were divided into Groups 1, 2, and 3, by infusion rates of 12, 24, and 36 mL/min. Groups 4 and 5 (3 pigs each) and Group 6 (2 pigs) underwent PIPP at the same respective infusion rates with and without AMA occlusion. Computed tomography (CT) arteriography was performed during PIPP with nonionic contrast media. The enhanced volume was calculated by adding the enhanced area in each slice using 1.25-mm axial images. The percent enhanced volume to the whole pancreas (%eV) was used to simulate drug distribution; the result was compared among groups.


Without AMA occlusion, a larger %eV was obtained with high infusion rates (P = 0.039). The median %eV in Groups 1, 2, and 3 were 57.7, 74.2, and 90.5%, respectively. With AMA occlusion, CT demonstrated duodenal enhancement at an infusion rate of 36 mL/min, and the median %eV in Groups 4, 5, and 6 were 92.8, 95.4, and 98.5%, respectively. A significantly larger %eV was obtained after AMA occlusion (P = 0.031).


A higher infusion rate or AMA occlusion increases the enhanced volume in PIPP in pig models.

Level of evidence

No level of evidence.


Isolation Pancreas Perfusion Intervention Computed tomography 



Financial supports for this study were provided by a Grant-in-Aid for Scientific Research (B, 23390306) and Early-Career Scientists (B, 15K19821) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

Compliance with Ethical Standards

Conflict of interest

We declare no conflicts of interest.


  1. 1.
    Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607–20.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Smeenk HG, Tran TC, Erdmann J, van Eijck CH, Jeekel J. Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch Surg. 2005;390:94–103.CrossRefPubMedGoogle Scholar
  3. 3.
    Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–79.CrossRefPubMedGoogle Scholar
  4. 4.
    Bria E, Milella M, Gelibter A, Cuppone F, Pino MS, Ruggeri EM, Carlini P, Nisticò C, Terzoli E, Cognetti F, Giannarelli D. Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progression? A meta-analysis of 20 phase 3 trials. Cancer. 2007;110:525–33.CrossRefPubMedGoogle Scholar
  5. 5.
    Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F, Gruppo Oncologico Italia Meridionale (GOIM), Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente (GISCAD), Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010;28:1645–51.CrossRefPubMedGoogle Scholar
  6. 6.
    Philip PA, Benedetti J, Corless CL, Wong R, O’Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest Oncology Group– directed intergroup trial S0205. J Clin Oncol. 2010;28:3605–10.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Homma H, Doi T, Mezawa S, Takada K, Kukitsu T, Oku T, Akiyama T, Kusakabe T, Miyanishi K, Niitsu Y. A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization. Cancer. 2000;89:303–13.CrossRefPubMedGoogle Scholar
  8. 8.
    Takamori H, Kanemitsu K, Hirota M, Ikeda O, Tanaka H, Beppu T, Yamashita Y, Oya N, Baba H. Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer. Ann Surg Oncol. 2011;18:1110–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Ikeda O, Kusunoki S, Kudoh K, Takamori H, Tsuji T, Kanemitsu K, Yamashita Y. Evaluation of the efficacy of combined continuous arterial infusion and systemic chemotherapy for the treatment of advanced pancreatic carcinoma. Cardiovasc Interv Radiol. 2006;29:362–70.CrossRefGoogle Scholar
  10. 10.
    Tanaka T, Sakaguchi H, Anai H, Yamamoto K, Morimoto K, Tamamoto T, Kichikawa K. Arterial infusion of 5-fluorouracil combined with concurrent radiotherapy for unresectable pancreatic cancer: results from a pilot study. Am J Roentgenol. 2007;189:421–8.CrossRefGoogle Scholar
  11. 11.
    Tanaka T, Yamamoto K, Sho M, Nishiofuku H, Inoue M, Sueyoshi S, Anai H, Sakaguchi H, Nakajima Y, Kichikawa K. Pharmacokinetic evaluation of pancreatic arterial infusion chemotherapy after unification of the blood supply in an animal model. J Vasc Interv Radiol. 2010;21:116–21.CrossRefPubMedGoogle Scholar
  12. 12.
    Murata S, Onozawa S, Mine T, Ueda T, Sugihara F, Yasui D, Kumita S, Shimizu A, Satake M. Minimizing systemic leakage of cisplatin during percutaneous isolated pancreas perfusion chemotherapy: a pilot study. Radiology. 2015;276:102–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, Figg WD, Zhai S, Beresneva T, Seidel GD, Alexander HR. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol. 2005;23:3465–74.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    van Iersel LB, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Putter H, Hartgrink HH, Kuppen PJ, Nortier JW, Tollenaar RA, van de Velde CJ. Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. Ann Oncol. 2008;19:1127–34.CrossRefPubMedGoogle Scholar
  15. 15.
    Wanebo HJ, DiSiena M, Begossi G, Belliveau J, Gustafson E. Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum. Ann Surg Oncol. 2008;15:1107–16.CrossRefPubMedGoogle Scholar
  16. 16.
    Murata S, Onozawa S, Sugihara F, Sakamoto A, Ueda T, Yamaguchi H, Yasui D, Mine T, Kumita S. Feasibility and safety of negative-balance isolated pelvic perfusion in patients with pretreated recurrent or persistent uterine cervical cancer. Ann Surg Oncol. 2015;22(12):3981–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Aigner KR, Gailhofer S. Celiac axis infusion and microembolization for advanced stage III/IV pancreatic cancer: a phase II study on 265 cases. Anticancer Res. 2005;25:4407–12.PubMedGoogle Scholar
  18. 18.
    Sasada T, Denno R, Tanaka T, Kanai M, Mizukami Y, Kohno S, Takabayashi A. Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study. Am J Clin Oncol. 2008;31:71–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Uwagawa T, Misawa T, Sakamoto T, Ito R, Gocho T, Shiba H, Wakiyama S, Hirohara S, Sadaoka S, Yanaga K. A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Ann Oncol. 2009;20:239–43.CrossRefPubMedGoogle Scholar
  20. 20.
    Tanaka T, Sakaguchi H, Anai H, Yamamoto K, Morimoto K, Nishiofuku H, Kichikawa K. Catheter position for adequate intra-arterial chemotherapy for advanced pancreatic cancer: evaluation with CT during arterial injection of contrast material. J Vasc Interv Radiol. 2004;15:1089–97.CrossRefPubMedGoogle Scholar
  21. 21.
    Li ES, Mu JX, Ji SM, Li XM, Xu LB, Chai TC, Liu JX. Total splenic artery embolization for splenic artery aneurysms in patients with normal spleen. World J Gastroenterol. 2014;14:555–60.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2018

Authors and Affiliations

  • Satoru Murata
    • 1
  • Shiro Onozawa
    • 2
  • Daisuke Yasui
    • 3
  • Tatsuo Ueda
    • 3
  • Fumie Sugihara
    • 3
  • Akira Shimizu
    • 4
  • Kenichi Suzuki
    • 5
  • Mitsuo Satake
    • 3
  1. 1.Radiology/Center for Interventional RadiologyTeikyo University Chiba Medical CenterChibaJapan
  2. 2.Departments of RadiologyTeikyo University Mizonokuchi HospitalKawasaki-shiJapan
  3. 3.Departments of Radiology/Center for Advanced Medical TechnologyNippon Medical SchoolTokyoJapan
  4. 4.Departments of Analytic Human PathologyNippon Medical SchoolTokyoJapan
  5. 5.Departments of Medical EngineeringNippon Medical SchoolTokyoJapan

Personalised recommendations